http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Low PR in ER(+)/HER2(−) breast cancer: high rates of <i>TP53</i> mutation and high SUV
Ahn, Sung Gwe,Yoon, Chang Ik,Lee, Jae Hoon,Lee, Hye Sun,Park, So Eun,Cha, Yoon Jin,Cha, Chihwan,Bae, Soong June,Lee, Kyung-A,Jeong, Joon Bioscientifica Ltd 2018 Endocrine-related cancer Vol.26 No.2
<P>On the basis of <I>TP53</I> mutations and standardized uptake values (SUVs) from 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET), we sought to enhance our knowledge of the biology underlying low progesterone receptor (PR) expression in estrogen receptor (ER)-positive/human epidermal growth factor receptor-2 (HER2)-negative tumors. This study included 272 patients surgically treated for ER-positive, HER2-negative breast cancer and who had undergone <I>TP53</I> gene sequencing. Of these, 229 patients also underwent 18F-FDG PET or PET/CT. Mutational analysis of exons 5–9 of the <I>TP53</I> gene was conducted using PCR amplification and direct sequencing. The SUVs were measured using 18F-FDG-PET scan images. Twenty-eight (10.3%) tumors had a somatic <I>TP53</I> mutation. The <I>TP53</I> mutation rate was significantly higher in low-PR tumors than in high-PR tumors (17.1% vs 7.9%, <I>P</I> = 0.039). Low-PR tumors had significantly higher median SUVs than high-PR tumors (<I>P</I> = 0.046). The multivariable analysis revealed that SUV and age remained independent variables associated with low PR expression. An adverse impact of low PR expression on recurrence-free survival was observed in the multivariable Cox regression hazard model. We provide clinical evidence that genetic alteration of the <I>TP53</I> gene and dysregulated glucose metabolism partly involve low PR expression in ER-positive and HER2-negative breast cancer.</P>
Protective effect of Korean red ginseng on oxaliplatin-mediated splenomegaly in colon cancer
Jeonghyun Kang,Joon Seong Park,Sung Gwe Ahn,Jin Hong Lim,Seung Hyuk Baik,Dong Sup Yoon,Kang Young Lee,Joon Jeong 대한외과학회 2018 Annals of Surgical Treatment and Research(ASRT) Vol.95 No.3
Purpose: This study investigated how adding Korean red ginseng extract (KRG) to folinic acid, fluorouracil and oxaliplatin (FOLFOX) chemotherapy affected the rate of splenomegaly in colon cancer. Methods: This retrospective study analyzed 42 patients who were randomly assigned to receive a FOLFOX regimen with or without KRG. Spleen volume change was assessed by computed tomography scans measured before surgery (presurgery volume) and 3 weeks after cessation of the 12th cycle of FOLFOX (postchemotherapy volume). Results: All patients showed increased spleen volume. No difference was observed in median presurgery and postchemotherapy volume between the KRG and control groups. However, a ratio defined as postchemotherapy volume divided by presurgery volume was significantly lower in the KRG group than the control group (median, 1.38 [range, 1.0–2.8] in KRG group vs. median, 1.89 [range, 1.1–3.0] in control group, P = 0.028). When splenomegaly was defined as a >61% increase in spleen volume, the rate of splenomegaly was significantly lower in the KRG group than the control group (28.6% vs. 61.9%, P = 0.03). KRG consumption was inversely associated with developing splenomegaly in multivariate analysis. Conclusion: Adding KRG during FOLFOX chemotherapy for colon cancer might protect against oxaliplatin-induced splenomegaly. The protective effect of Korean red ginseng should be investigated with further research.
Protective effect of Korean red ginseng on oxaliplatin-mediated splenomegaly in colon cancer
Kang, Jeonghyun,Park, Joon Seong,Ahn, Sung Gwe,Lim, Jin Hong,Baik, Seung Hyuk,Yoon, Dong Sup,Lee, Kang Young,Jeong, Joon The Korean Surgical Society 2018 Annals of Surgical Treatment and Research(ASRT) Vol.95 No.3
<P><B>Purpose</B></P><P>This study investigated how adding Korean red ginseng extract (KRG) to folinic acid, fluorouracil and oxaliplatin (FOLFOX) chemotherapy affected the rate of splenomegaly in colon cancer.</P><P><B>Methods</B></P><P>This retrospective study analyzed 42 patients who were randomly assigned to receive a FOLFOX regimen with or without KRG. Spleen volume change was assessed by computed tomography scans measured before surgery (presurgery volume) and 3 weeks after cessation of the 12th cycle of FOLFOX (postchemotherapy volume).</P><P><B>Results</B></P><P>All patients showed increased spleen volume. No difference was observed in median presurgery and postchemotherapy volume between the KRG and control groups. However, a ratio defined as postchemotherapy volume divided by presurgery volume was significantly lower in the KRG group than the control group (median, 1.38 [range, 1.0–2.8] in KRG group vs. median, 1.89 [range, 1.1–3.0] in control group, P = 0.028). When splenomegaly was defined as a >61% increase in spleen volume, the rate of splenomegaly was significantly lower in the KRG group than the control group (28.6% <I>vs</I>. 61.9%, P = 0.03). KRG consumption was inversely associated with developing splenomegaly in multivariate analysis.</P><P><B>Conclusion</B></P><P>Adding KRG during FOLFOX chemotherapy for colon cancer might protect against oxaliplatin-induced splenomegaly. The protective effect of Korean red ginseng should be investigated with further research.</P>
Jason Joon Bock Lee,Jinhyun Choi,Sung Gwe Ahn,Joon Jeong,Ik Jae Lee,Kwangwoo Park,Kangpyo Kim,Jun Won Kim 대한방사선종양학회 2017 Radiation Oncology Journal Vol.35 No.2
Purpose: To report the results of a correlation analysis of skin dose assessed by in vivo dosimetry and the incidence of acute toxicity. This is a phase 2 trial evaluating the feasibility of intraoperative radiotherapy (IORT) as a boost for breast cancer patients. Materials and Methods: Eligible patients were treated with IORT of 20 Gy followed by whole breast irradiation (WBI) of 46 Gy. A total of 55 patients with a minimum follow-up of 1 month after WBI were evaluated. Optically stimulated luminescence dosimeter (OSLD) detected radiation dose delivered to the skin during IORT. Acute toxicity was recorded according to the Common Terminology Criteria for Adverse Events v4.0. Clinical parameters were correlated with seroma formation and maximum skin dose. Results: Median follow-up after IORT was 25.9 weeks (range, 12.7 to 50.3 weeks). Prior to WBI, only one patient developed acute toxicity. Following WBI, 30 patients experienced grade 1 skin toxicity and three patients had grade 2 skin toxicity. Skin dose during IORT exceeded 5 Gy in two patients: with grade 2 complications around the surgical scar in one patient who received 8.42 Gy. Breast volume on preoperative images (p = 0.001), ratio of applicator diameter and breast volume (p = 0.002), and distance between skin and tumor (p = 0.003) showed significant correlations with maximum skin dose. Conclusions: IORT as a boost was well-tolerated among Korean women without severe acute complication. In vivo dosimetry with OSLD can help ensure safe delivery of IORT as a boost.